EVP & General Counsel of Acadia Pharmaceuticals Inc (30-Year Financial, Insider Trades) Austin D. Kim (insider trades) sold 17,500 shares of ACAD on 12/11/2019 at an average price of $45.06 a share. The total sale was $788,550.
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia. ACADIA Pharmaceuticals Inc has a market cap of $6.83 billion; its shares were traded at around $44.34 with and P/S ratio of 20.98.
CEO Recent Trades:
- CEO Stephen Davis sold 150,000 shares of ACAD stock on 12/05/2019 at the average price of $52.34. The price of the stock has decreased by 15.28% since.
CFO Recent Trades:
- EVP and CFO Elena Ridloff sold 36,000 shares of ACAD stock on 12/09/2019 at the average price of $49.66. The price of the stock has decreased by 10.71% since.
Directors and Officers Recent Trades:
- EVP and CCO Michael J. Yang sold 105,479 shares of ACAD stock on 12/12/2019 at the average price of $44.46. The price of the stock has decreased by 0.27% since.
- EVP & General Counsel Austin D. Kim sold 17,500 shares of ACAD stock on 12/11/2019 at the average price of $45.06. The price of the stock has decreased by 1.6% since.
- EVP and CCO Michael J. Yang sold 14,521 shares of ACAD stock on 12/09/2019 at the average price of $50.46. The price of the stock has decreased by 12.13% since.
- President Srdjan R. Stankovic sold 2,160 shares of ACAD stock on 11/19/2019 at the average price of $46.41. The price of the stock has decreased by 4.46% since.
For the complete insider trading history of ACAD, click here
.
